Source-grounded facts extracted from Valion Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Valion Bio, Inc. shareholders approved Approval of sale and issuance of common stock pursuant to Common Stock Purchase Agreement with Tumim Stone Capital, LLC (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 333,345 153,008”
Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Series B Non-Voting Convertible Preferred Stock and exercise of related warrants to 3i, LP (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 333,682 152,377 135,011* 637,190”
Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Senior Secured Convertible Note and exercise of warrant to 3i, LP (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 332,456 153,503 135,111* 637,190”
Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Series C Preferred Stock and exercise of related warrants (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 332,353 153,606 135,111* 637,190”
Valion Bio, Inc. shareholders approved Ratification of Rosenberg Rich Baker Berman, P.A. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-28 meeting.
“Proposal No. 3: The Company’s stockholders ratified the selection of Rosenberg Rich Baker Berman, P.A.”
Valion Bio, Inc. shareholders approved Approval of Plan Amendment to increase shares authorized under the 2021 Amended and Restated 2021 Equity Incentive Plan by 2,581,608 shares at the 2026-05-28 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 736,919 134,918 60,707 637,190”
Valion Bio, Inc. shareholders approved Election of one Class II director at the 2026-05-28 meeting.
“Name of Director Votes For Withhold Broker Non-Votes Dean Zikria 873,001 59,543 637,190”
Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs at Valion Bio, Inc..
“On May 4, 2026, Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs of Valion Bio, Inc.”
Valion Bio, Inc.: Changed corporate name from Tivic Health Systems, Inc. to Valion Bio, Inc (effective 2026-04-28).
“On April 22, 2026, Tivic Health Systems, Inc. (the “Company”) filed a certificate of amendment (“Certificate of Amendment”) to its amended and restated certificate of incorporation filed with the Delaware Secretary of State to change its corporate name to Valion Bio, Inc. (the “Name Change”), effective as of April 28, 2026.”
Valion Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“March 19, 2026, Tivic Health Systems, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days, the Company is not currently in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notification has no immediate effect”
Valion Bio, Inc. entered into Office Sublease with Texas Research and Technology Foundation valued at Monthly base rent starting at $31,044.94 with annual increases of approximately 3.0% (effective 2026-03-13).
“On March 13, 2026, VBI entered into a Sublease (the “Office Sublease” and together with the Microbial Building Lease and the Mammalian Building Lease, the “Facility Leases”) with Texas Research and Technology Foundation (“TRTF”) to sublease approximately 8,122 square feet of office space located at the Property, which Office Sublease was consented to by TPB, as landlord of the leased premises, and is subject to the terms of that certain Office Lease Agreement, dated June 1, 2024, by and between TRTF and TPB.”
Valion Bio, Inc. entered into Mammalian Building Lease with Merchants Ice II, LLC valued at Monthly base rent of $55,029.73 for first twelve months, aggregate base rent over lease term approxi (effective 2026-01-01).
“On March 9, 2026, VBI entered into a Lease (the “Mammalian Building Lease”) with Merchants Ice II, LLC (“Merchants Ice II”) to lease an approximately 20,144 square foot facility located at the Property.”
Valion Bio, Inc. entered into Microbial Building Lease with TPB Merchants Ice LLC valued at Monthly base rent of approximately $22,605 for first twelve months, aggregate base rent over eight-y (effective 2026-03-13).
“On March 13, 2026, Tivic Health Systems, Inc.’s (the “Company”) wholly owned subsidiary Velocity Bioworks, Inc. (“VBI”) entered into a Building Lease Agreement (the “Microbial Building Lease”) with TPB Merchants Ice LLC (“TPB”) to lease an approximately 8,024 square foot facility (the “Microbial Building”) located at 1305 E. Houston St., San Antonio, TX 78205 (the “Property”).”
Valion Bio, Inc. entered into Common Stock Purchase Agreement with Tumim Stone Capital, LLC valued at Up to $50,000,000 of newly issued shares of Common Stock (effective 2026-02-06).
“On February 6, 2026, Tivic Health Systems, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Tumim Stone Capital, LLC, a Delaware limited liability company (the “Investor”).”
Valion Bio, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock, effective upon filing on December 9, 2025 (effective 2025-12-09).
“On December 9, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Preferred Offering discussed above in Item 1.01. The Certificate of Designation became effective upon filing and designates 75,000 shares of the Company’s preferred stock as Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share.”
Valion Bio, Inc. incurred senior notes of $16,253,147.10 with 3i at 5.0% per annum maturing fifth anniversary of the issuance date.
“a senior secured convertible note (the “Note”) in the principal amount of $16,253,147.10”
Valion Bio, Inc. completed an acquisition involving 3i, LP, as collateral agent for Scorpius Holdings, Inc. for $16,253,147.10 in cash (closed 2025-12-10).
“provide similar services to other clients in the future. Pursuant to the APA, as consideration for the Acquired Assets, the Company (on behalf of VBI) paid the Collateral Agent $16,253,147.10 in cash at closing of the Acquisition. Consistent with customary practices in a sale under Article 9, the APA does not contain representations, warranties, covenants or”
Michael Handley was appointed as Chief Operating Officer and President of Tivic Biopharma division at Valion Bio, Inc..
“On February 18, 2025, Michael Handley was appointed as Chief Operating Officer of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), and President of the Company’s Tivic Biopharma division.”
Valion Bio, Inc. received a nasdaq delisting notice notice regarding stockholders equity.
“December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically”
Valion Bio, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically”
Lisa Wolf was appointed as interim Chief Financial Officer and Principal Financial and Principal Accounting Officer at Valion Bio, Inc..
“Effective October 1, 2024, Lisa Wolf has been appointed as the Company’s new interim Chief Financial Officer and Principal Financial and Principal Accounting Officer.”
Kimberly Bambach departed as interim Chief Financial Officer at Valion Bio, Inc..
“On September 12, 2024, Kimberly Bambach tendered her resignation from her role as interim Chief Financial Officer of the Company, effective October 1, 2024.”
Karen Drexler resigned as director at Valion Bio, Inc..
“On June 17, 2024, Karen Drexler tendered her resignation from the Board and each of the Compensation Committee, Audit and Risk Committee and Nominations and Corporate Governance Committee thereof, in each case effective September 30, 2024.”
Christina Valauri was appointed as director at Valion Bio, Inc..
“On June 17, 2024, the board of directors (the “Board”) of Tivic Health Systems, Inc. (the “Company”) appointed Christina Valauri as a director of the Company, effective July 1, 2024”
Valion Bio, Inc. reported first quarter 2024 results: revenue $334 thousand.
“Revenue for Q1 2024 was $334 thousand, compared to $376 thousand for Q1 2023, a decrease of $42 thousand, or 11%, due reduced unit sales volume offset by increased selling price.”
Valion Bio, Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at $280,245.00 (effective 2024-05-09).
“On May 9, 2024, the Company and the Placement Agent entered into a Placement Agency Agreement (the “Placement Agency Agreement”), pursuant to which, as compensation for services rendered by the Placement Agent in connection with the Offering, the Company agreed to pay the Placement Agent an aggregate cash fee of 7.0% of the gross proceeds of the Offering (amounting to $280,245.00) at closing, as well as $100,000.00 for the reimbursement of certain of the Placement Agent’s expenses.”
Valion Bio, Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $4.0 million (effective 2024-05-09).
“On May 9, 2024, Tivic Health Systems, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue, and deliver, in a registered public offering (the “Offering”) (i) 4,710,000 shares (“Shares”) of common stock (the “Common Stock”), par value $0.0001 per share, (ii) 4,710,000 Series A warrants (the “Series A Warrants”) to purchase up to 4,710,000 shares of Common Stock and (iii) 7,065,000 Series B warrants (the “Series B Warrants” and collectively with the Series A Warrants, the “Common Warrants”) to purchase up to 7,065,000 shares of Common Stock, to the Investors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.